Wockhardt eyes 20% YoY growth

Chairman Habil Khorakiwala in the company's annual general meeting (AGM) stated that he expects to clock in a 20% year-on-year growth on the back of its private label over the counter (OTC) products, first to file (FTF) opportunities and biotech foray. “The paediatrics vertical will be a major growth driver. We will also explore FTF opportunities for growth. And, the derivative-related losses will be made up in time.”

The management also indicated that it expects all issues of its corporate debt restructuring (CDR) process to be settled by the end of FY11. “The EU loan restructure is near completion. And, the FCCB issue too has been settled,” he added.